Illumina, Inc. (NASDAQ:ILMN) today announced that it will issue results
for first quarter 2009 following the close of market on Tuesday, April
21, 2009.
On the same day, at 2:00pm Pacific Time (5:00pm Eastern Time) Jay
Flatley, President and Chief Executive Officer, and Christian Henry,
Senior Vice President and Chief Financial Officer, will host a
conference call with analysts, investors, and other interested parties
to discuss financial and operating results.
Conference Call Details
The conference call will begin at 2:00pm Pacific Time (5:00pm Eastern
Time) on Tuesday, April 21, 2009. Interested parties may listen to the
call by dialing 1-800-901-5218 (passcode: 98415934), or if outside North
America, by dialing +1-617-786-4511 (passcode: 98415934). Individuals
may access the live teleconference under the "Corporate/Investor
Information" tab of Illumina's web site at www.illumina.com.
A replay of the conference call will be available from 5:00pm Pacific
Time (8:00pm Eastern Time) on April 21, 2009 through April 28, 2009 by
dialing 1-888-286-8010 (passcode: 36595744) or if outside North America,
by dialing +1-617-801-6888 (passcode: 36595744).
About Illumina
Illumina (www.illumina.com)
is a leading developer, manufacturer, and marketer of next-generation
life-science tools and integrated systems for the large-scale analysis
of genetic variation and biological function. Using our proprietary
technologies, we provide a comprehensive line of products and services
that currently serve the sequencing, DNA analysis, and gene expression
markets, and we expect to enter the market for molecular diagnostics.
Our customers include leading genomic research centers, pharmaceutical
companies, academic institutions, clinical research organizations, and
biotechnology companies. Our tools provide researchers around the world
with the performance, throughput, cost effectiveness, and flexibility
necessary to perform the billions of genetic tests needed to extract
valuable medical information from advances in genomics and proteomics.
We believe this information will enable researchers to correlate genetic
variation and biological function, which will enhance drug discovery and
clinical research, allow diseases to be detected earlier, and permit
better choices of drugs for individual patients.
“Safe Harbor” Statement under the Private Securities Litigation Reform
Act of 1995: this release may contain forward-looking statements that
involve risks and uncertainties. Among the important factors that could
cause actual results to differ materially from those in any
forward-looking statements are Illumina’s ability (i) to integrate
effectively our recent acquisition of Solexa, Inc., (ii) to develop and
commercialize further our BeadArray™, VeraCode®, and Solexa®
technologies and to deploy new sequencing, gene expression, and DNA
analysis products and applications for our technology platforms, (iii)
to manufacture robust microarrays and Oligator® oligonucleotides, (iv)
to integrate and scale our VeraCode technology, together with other
factors detailed in our filings with the Securities and Exchange
Commission including our recent filings on Forms 10-K and 10-Q or in
information disclosed in public conference calls, the date and time of
which are released beforehand. We disclaim any intent or obligation to
update these forward-looking statements beyond the date of this release.
Media:
Maurissa Bornstein
Public Relations Manager
858-332-4055
mbornstein@illumina.com
or
Investors:
Peter
J. Fromen
Sr. Director, Investor Relations
858-202-4507
pfromen@illumina.com
